According to a recent market study published by Growth Market Reports, titled, "Global Lidocaine Jelly and Gels Market by product types, by applications, by distribution channels, and by regions: Size, Share, Trends and Opportunity Analysis, 2017-2027", the market was valued at USD 166.1 Million in 2019 and is expected to grow at a rate of 3.7% by the year 2027. The global lidocaine jelly and gels market is anticipated to grow significantly during the forecast period. Multiple applications such as dentistry, urology, and tattoos, growth of OTC drugs segment, rising adoption of e-pharmacies, and increasing healthcare expenditure are some of the factors contributing to the market growth.

Request a free sample copy @ https://growthmarketreports.com/request-sample/2606

The global lidocaine jelly and gels market has been segmented into product types, applications, distribution channels, and regions. In terms of product types, the global lidocaine jelly and gels market is bifurcated into Rx and OTC. Based on applications, the market has been segmented into interstitial cystitis/bladder pain syndrome, pain relief in urethritis and others.

On the basis of distribution channels, the global lidocaine jelly and gels market has been segregated into hospital pharmacy, retail pharmacy and e-commerce. On the basis of regions, the market is segmented as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Lidocaine jelly is prominently used during catheter insertion. The cases related to urinary catheter insertion rising; for instance, in the US alone, the electronic health records identified 148,361 indwelling catheterizations, of which 61,047 were for three or more days, in five hospitals. The Lidocaine gels is a primary product used during long catheterizations, as patients need numbness to bear long treatment schedules, which in turn, fuels the need for lidocaine gels, thereby propelling the market during the forecast period.


Globally, the impact of COVID-19 disturbed the economic growth of several countries such as India, the UK, France, Italy, Germany, and the US. The production of lidocaine gels was kept on hold or delayed in second quarter of 2020, as the supply of the products was restricted globally. Currently, production facilities are 50% capacity to cater to the demand for lidocaine gels. Supply of the jelly and gels through e-commerce distribution channels is increasing, as many consumers prefer to avoid OTC purchases and opt for online mode to order self-care products.

Key Takeaways from the Study

  • The interstitial cystitis/bladder pain syndrome segment is expected to hold a significant share of the market and is anticipated to expand at a considerable CAGR during the forecast period, due to rising awareness regarding health among people and increasing incidences of bladder pain syndrome.
  • The Rx segment is expected to hold a significant share of the market during the forecast period due to high adoption of prescription drugs, as prescription drugs enable patients to opt for treatments that are suitable to their health orientations and medical history.
  • The US holds a substantial share of the market. The demand for OTC drugs is rising in the US, as stores in the country often sell private label OTC products, which are extensively used due to the lower cost than the Rx products.
  • Italy has the highest percentage of people adopting tattoos, which in turn, is propelling the market for lidocaine jelly and gels in the country.
  • On the basis of distribution channel, the hospital pharmacies segment held 54% value share of the market in 2019. The segment is projected to account for the largest share of the market during the forecast period.
  • In terms of revenue, the hospital pharmacies and retail pharmacies segments were valued at USD 89.5 Mn and USD 56 Mn, respectively, in 2019.
  • Furthermore, the retail pharmacies segment is anticipated to expand at a lucrative CAGR of 3.6% between 2020 and 2027.
  • The Hospital Pharmacies segment was valued at USD 89.5 Million in 2019. The overall incremental opportunity between 2019 and 2027 is expected to be valued at USD 25.6 Million.

Report Scope

Report Metric

Details

Market Value in 2019

USD 166.1 Million

Market Growth Rate (from 2020 to 2027)

3.7%

Historical Data

2017 & 2018

Base Year

2019

Forecast Period

2020 – 2027

Market Segments

Product Types, Applications, Distribution Channels, and Regions

Region Scope

North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Key Companies Profiled

Akorn, Incorporated, Aspen Pharmacare Holdings Limited, AstraZeneca, Curatio Healthcare Private Limited, ESBA Laboratories Inc., and FARCO-PHARMA GmbH.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail tailor-made purchase options to meet your research requirements.

Target Audience

  • Demand Side: Hospitals, Generic Medication, E-Pharmacy, and others.
  • Regulatory Side: Concerned government authorities, The Globally Harmonized System of Classification and Labelling of Chemicals (GHS), commercial research & development (R&D) institutions, and other regulatory bodies.
  • Associations and Industry Bodies: Food and Drug Administration, Columbia University, Mountain States Tumor and Medical Research Institute, and others.